Thus, concerning ANS/inflammation anti-obesity, we identified phelligridin E (a natural product), which could block the FOX1-DBD interaction by interfering with the FOX1-DNA binding sites and constitute a key active substance of novel anti-obesity drug(s). This evidence concerns the gene RBFOX1 and obesity disorder.